Is Battered CannTrust (TSX:TRST) Stock a Buy or Sell?

The shameful incident involving the former top executives is causing a lot of headaches for CannTrust Holdings Inc. (TSX:TRST)(NYSE:CTST). Investors are warned not touch the stock with a 10-foot pole.

Dice engraved with the words buy and sell

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Are we seeing distress signals from CannTrust (TSX:TRST)(NYSE:CTST)? Call it grave misconduct or fraud, but the licensed cannabis operator had it coming. The scandal at CannTrust is also hurting the whole cannabis industry and is affecting investor confidence.

The stock has plummeted to $2.87 last week when the price stood at a high of $13.45 just four months ago. CannTrust is sinking and has lost about 60% in market value in less than a month. A temporary suspension of the licence could be the repercussion. But a complete revocation of the licence could spell doom for the company.

The discovery

No one expected CannTrust would intentionally skirt legal cannabis cultivation laws. The company’s expelled CEO Peter Aceto and resigned chairman Eric Paul were in cahoots to hide the unlawful growing of cannabis in five unlicensed cultivation rooms.

CannTrust’s former top executives knew about the shenanigans, as confirmed by the company’s internal e-mails. The bosses could have stopped the illegal activities upon learning about them last November. Instead, the two consented and turned into black marketers.

The sinister plot was discovered when Health Canada conducted an inspection in June. CannTrust was cultivating and selling unlicensed cannabis since October 2018 before getting the cultivation licences in April this year. In July, management admitted to the violations.

Some cannabis products grown inside the unlicensed rooms at CannTrust’s Niagara facility have already been shipped. It is possible that the products can be found in all 10 Canadian provinces where the company has supply deals.

Seizing the contraband

Health Canada took hold of 5,200 kilos from the five rooms while CannTrust placed on hold 7,500 kilos being kept at the Vaughan facility. The total inventory seized by the regulating agency is just 3% of CannTrust’s potential peak annual capacity production of 400,000 kilos. Sale operations were also stopped.

Health Canada is still conducting quality tests and will release the results soon. CannTrust might partially or totally lose the 12,700 kilos. But what is unknown at this point is the magnitude of the penalties or fines. As mentioned earlier, a temporary or full licence revocation is a strong possibility.

CannTrust is definitely in dire straits, despite the statement of Robert Marcovitch, the newly appointed interim CEO. He expressed confidence that the company will return to full compliance with Health Canada after completion of the exhaustive investigation.

Buyers in waiting

With CannTrust in the freezer, management should carefully evaluate the options. Another Canadian cannabis producer that is not one of four growers with supply deals in all 10 Canadian provinces might attempt to make a pitch for CannTrust.

Acquiring CannTrust is good for a prospective buyer who wants to focus on the cannabis derivatives market. CannTrust’s outdoor production can run up to 200,000 kilos, and outdoor cannabis is ideal for extraction.

The events at CannTrust leave a bad taste in the mouth. Many lost money when the stock sunk to an all-time low. Restoring investor trust and confidence is inconceivable. No one would dare recommend a buy rating for the stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »